Latest stories on IBRX
ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy Now
Yahoo Finance61 · neutralanalyst
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026 | IBRX Stock News
StockTitan61 · neutralproduct/pr
ImmunityBio (IBRX) Health Economic Analysis Highlights ANKTIVA Value Over TAR-200
Yahoo Top67 · bullishproduct/pr
Is ImmunityBio Inc. (IBRX) One of the Best Momentum Stocks to Buy According to Analysts?
Yahoo Finance61 · neutralanalyst
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Morningstar22 · bearishgeneral
ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout
Seeking Alpha77 · bullishproduct/pr
ImmunityBio rises as Anktiva label expansion undergoes FDA review
Seeking Alpha67 · bullishproduct/pr
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Morningstar22 · bearishgeneral
ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM
Seeking Alpha68 · bullishanalyst
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
PR Newswire33 · bearishgeneral
ImmunityBio Secures Exclusive Tokyo-172 BCG Rights in U.S.
TipRanks67 · bullishproduct/pr
ImmunityBio acquiring U.S. rights to Tokyo strain of BCG
Seeking Alpha67 · bullishproduct/pr